Patents by Inventor Denis BUCHER

Denis BUCHER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12065443
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: August 20, 2024
    Assignee: GALAPAGOS NV
    Inventors: Luke Jonathan Alvey, Denis Maurice Annoot, Florence Marie-Emilie Bonnaterre, Denis Bucher, Béranger Duthion, Hélène Marie Jary, Christophe Peixoto, Taoues Temal-Laib, Amynata Tirera, Nicolas Desroy
  • Publication number: 20230072235
    Abstract: The present invention relates to a research tool for structural biology, in particular to enhance the determination of the three-dimensional structure of biological macromolecules. More specifically, the invention serves to improve the overall feasibility of structure determination providing higher resolution and better quality of the three-dimensional structures of proteins by complex-formation with a novel fusion polypeptide.
    Type: Application
    Filed: February 16, 2021
    Publication date: March 9, 2023
    Inventors: Stephan SCHENCK, Denis BUCHER
  • Publication number: 20220402911
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2a, X, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNF?, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: May 29, 2019
    Publication date: December 22, 2022
    Inventors: David AMANTINI, Reginald Christophe Xavier BRYS, Denis BUCHER, Steve Irma Joel DE VOS, Nicolas DESROY, Agnès Marie JONCOUR, Christophe PEIXOTO, Taoues TEMAL-LAÏB, Amynata TIRERA
  • Publication number: 20220340548
    Abstract: The present invention discloses compounds according to Formula I: wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNF?, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: May 25, 2020
    Publication date: October 27, 2022
    Inventors: Luke Jonathan ALVEY, Denis BUCHER, Nicolas DESROY, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAÏB, Amynata TIRERA, Florence Marie-Emilie BONNATERRE, Béranger DUTHION
  • Publication number: 20220340581
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 27, 2022
    Inventors: Luke Jonathan ALVEY, Denis Maurice ANNOOT, Florence Marie-Emilie BONNATERRE, Denis BUCHER, Béranger DUTHION, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAIB, Amynata TIRERA, Nicolas DESROY
  • Patent number: 11339166
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: May 24, 2022
    Assignee: GALAPAGOS NV
    Inventors: Luke Jonathan Alvey, Denis Maurice Annoot, Florence Marie-Emilie Bonnaterre, Denis Bucher, Béranger Duthion, Hélène Marie Jary, Christophe Peixoto, Taoues Temal-Laib, Amynata Tirera, Nicolas Desroy
  • Publication number: 20210395225
    Abstract: The present invention relates to novel antagonists of the A2B adenosine receptor and pharmaceutical compositions comprising said antagonists as well as their uses for the treatment and prevention of disorders known to be susceptible to improvement by antagonism of the A2B receptor such as asthma, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, vascular diseases, allergic diseases, hypertension, retinopathy, diabetes mellitus, inflammatory gastrointestinal tract disorders, inflammatory diseases, autoimmune diseases, renal diseases, neurological disorders and, in particular, cancers.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 23, 2021
    Inventors: Werner NEIDHART, Denis BUCHER
  • Publication number: 20210101903
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: November 26, 2018
    Publication date: April 8, 2021
    Inventors: Luke Jonathan ALVEY, Denis Maurice ANNOOT, Florence Marie-Emilie BONNATERRE, Denis BUCHER, Béranger DUTHION, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAIB, Amynata TIRERA, Nicolas DESROY